Abstract describes efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial.

Source: New promise for patients with primary progressive multiple sclerosis


David Cottle

UBB Owner & Administrator